ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
US clears Cara, Vifor's Korsuva to treat itching in CKD patients
August 24, 2021Cara Therapeutics and Vifor Pharma said Monday that the FDA has approved Korsuva (difelikefalin) to treat moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing haemodialysis. -
Treatment for hyperkalaemia recommended by NICE for NHS
December 19, 2019NICE has recommended patients in England have access to a new treatment option for treating hyperkalaemia (raised serum potassium levels) in adults. -
Vifor Fresenius snap up rights to Cara’s itch therapy
May 25, 2018The joint partnership between Vifor Pharma and Fresenius Medical Care, Vifor Fresenius, has put down $50 in upfront cash and an equity investment of $20 million to gain the Ex-US, Japan and South Korea rights to Cara Therapeutics’ Korsuva. -
Vifor’s hyperkalaemia drug Veltassa approved in Europe
July 24, 2017Vifor Pharma has gained final European marketing approval for its hyperkalaemia treatment Veltassa.
Pharma Sources Insight January 2025
